Teladoc Health (TDOC)
(Delayed Data from NYSE)
$7.17 USD
+0.07 (0.99%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $7.18 +0.01 (0.14%) 7:58 PM ET
3-Hold of 5 3
A Value A Growth C Momentum A VGM
Teladoc (TDOC) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.65 | $19.00 | $8.00 | 48.54% |
Price Target
Based on short-term price targets offered by 20 analysts, the average price target for Teladoc comes to $10.65. The forecasts range from a low of $8.00 to a high of $19.00. The average price target represents an increase of 48.54% from the last closing price of $7.17.
Analyst Price Targets (20)
Broker Rating
Teladoc currently has an average brokerage recommendation (ABR) of 2.56 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 25 brokerage firms. The current ABR compares to an ABR of 2.54 a month ago based on 24 recommendations.
Of the 25 recommendations deriving the current ABR, five are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 20% and 4% of all recommendations. A month ago, Strong Buy made up 20.83%, while Buy represented 4.17%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/TDOC.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 5 | 5 | 5 | 5 | 5 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 19 | 19 | 18 | 18 | 18 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 2.56 | 2.56 | 2.54 | 2.54 | 2.54 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/28/2024 | KeyBanc Capital Markets | Scott Schoenhaus | Hold | Hold |
8/5/2024 | UBS | Kevin Caliendo | Not Available | Hold |
8/2/2024 | Cantor Fitzgerald & Co | Sarah James | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/1/2024 | Needham & Company | Ryan Macdonald | Hold | Hold |
8/1/2024 | Stephens | Jeffrey Garro | Hold | Hold |
8/1/2024 | Cowen & Co. | Charles Rhyee | Hold | Hold |
8/1/2024 | Evercore Partners | Elizabeth Anderson | Hold | Hold |
8/1/2024 | Truist Securities | Jailendra Singh | Hold | Hold |
8/1/2024 | Canaccord Genuity | Richard Close | Strong Buy | Strong Buy |
8/1/2024 | D.A. Davidson | Gil Luria | Hold | Hold |
7/31/2024 | William Blair | Ryan S Daniels | Hold | Hold |
7/31/2024 | Not Identified | Not Identified | Hold | Hold |
7/26/2024 | Piper Sandler | Jessica E Tassan | Strong Buy | Strong Buy |
7/1/2024 | Guggenheim Securities | Jack D Wallace | Hold | Hold |
6/16/2024 | SVB Securities | Michael Cherny | Hold | Hold |
4/29/2024 | Wells Fargo Securities | Stan Berenshteyn | Hold | Hold |
4/26/2024 | Not Identified | Not Identified | Moderate Buy | Moderate Buy |
2/21/2024 | Not Identified | Not Identified | Hold | Hold |
1/2/2024 | BTIG | David M Larsen | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.56 |
ABR (Last week) | 2.56 |
# of Recs in ABR | 25 |
Average Target Price | $10.65 |
LT Growth Rate | NA |
Industry | Medical Services |
Industry Rank by ABR | 172 of 253 |
Current Quarter EPS Est: | -0.28 |